TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03801122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid, with 3 injections/8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid, with 3 injections/8 hours.
Study: NCT03017300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT®
Description: A device used to offer threshold load to inspiratory muscle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFLEX®
Description: A device used to offer resisive to inspiratory muscle
Study: NCT03226951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthreshold 532nm laser
Description: Subthershold 532nm laser
Study: NCT01143779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
Study: NCT02811731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/5mg - B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg and Amlodipine 5mg
Study: NCT02674815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training Exercise programme
Description: High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
Study: NCT03896204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-suppoted joint protection technique
Description: After joint protection technics training, patients will be followed up with telephone support for 1 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint protection technique training
Description: Training will be given to individuals about joint protection technique
Study: NCT02938299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2 + L19TNF
Description: Mixture of L19IL2 and L19TNF once weekly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection of melanoma tumor lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of melanoma tumor lesions
Study: NCT02077010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nebulized milrinone
Description: inhaled nebulized milrinone 60mg/4ml
Study: NCT04474834

Intervention type: GENETIC
Intervention: Polygenic Risk Score
Description: A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40 %).
Study: NCT04323124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07059013
Description: Participants will recieve PF-07059013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will recieve placebo
Study: NCT03995134

Intervention type: COMBINATION_PRODUCT
Intervention: Propofol and Remifentanil administered by TCI pump
Description: Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
Study: NCT04587336

Intervention type: BEHAVIORAL
Intervention: Cognitive Interview
Description: Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.

Intervention type: BEHAVIORAL
Intervention: Baseline Survey
Description: Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: Qualitative Interviews: Describe self-management challenges and preferred learning strategies to inform intervention components and delivery approach for Veterans with T2D.

Intervention type: BEHAVIORAL
Intervention: TARDIS Photo Elicitation
Description: TARDIS Photo Elicitation: Using visual-based qualitative methods to help identify and more robustly describe DD in Veterans.

Intervention type: BEHAVIORAL
Intervention: TARDIS Intervention
Description: TARDIS Intervention: Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
Study: NCT02201953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04789772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
Study: NCT00577473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
Study: NCT00508794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: 3 sessions of yoga each week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Control Group
Description: 3 sessions of stretching each week for 6 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control Group
Description: Option of participating in the yoga or stretching program after the study has ended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
Study: NCT03889808

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of serum anti-toxin Abs for C. difficile
Study: NCT02202421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Applied Behavior Analysis (T-ABA)
Description: Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Applied Behavior Analysis (T-ABA)
Description: Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
Study: NCT00199381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Study: NCT03887923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Physical Therapy
Description: Balance, Gaze Stabilization, Habituation, and Walking exercises
Study: NCT03406377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPK-88003
Description: OPK-88003 subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT00385671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Duloxetine (DLX) once daily (QD), orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Duloxetine (DLX) once daily (QD), orally (PO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Pregabalin (PGB) orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
Study: NCT01586364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60Mg Oral Tablet
Study: NCT02363920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HOF
Description: the addition of high oxygen flow to patients breathing spontaneously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: noninvasive mechanical ventilation (NIV)
Description: the addition of a ventilatory support delivered with a oro-nasal interface
Study: NCT03198715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS1040b
Description: DS-1040b in solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS1040b
Description: DS-1040b in solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS1040b
Description: DS-1040b in solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS1040b
Description: DS-1040b in solution for intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for intravenous infusion
Study: NCT00092417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Varicella Zoster Virus Vaccine
Description: Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Varicella Zoster Virus Vaccine
Description: Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
Study: NCT02769117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound on fractured bone
Description: A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound on contralateral intact bone
Description: A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
Study: NCT04436354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginoscopic office hysteroscopy
Description: comparison of procedural time and pain scores of patients in different gynecologycal positions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginoscopic office hysteroscopy
Description: comparison of procedural time and pain scores of patients in different gynecologycal positions
Study: NCT04230889

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Diet Group
Description: three main meals and two snacks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Nutritional Shake
Description: 2 servings per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Nutritional Shake
Description: 2 servings per day
Study: NCT03549936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low lactose or regular formula
Description: If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low lactose or regular formula
Description: If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B.
Study: NCT02273479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin®
Description: Asasantin® extended release (RAD-SP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01600326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tenotomy (no injection)
Description: Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided platelet rich plasma injection
Description: Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy.
Study: NCT00751296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
Study: NCT01972217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone or prednisolone
Description: Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone or prednisolone
Description: Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
Study: NCT00394095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Oral topiramate 300-400mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to Experimental arm
Study: NCT03248908

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pupillary dilation reflex
Description: Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pupillary dilation reflex
Description: Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
Study: NCT00577473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine
Description: mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
Study: NCT03248908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
Study: NCT01611844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)
Description: 2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)
Description: 2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right
Study: NCT03234322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: external validated risk prediction model
Description: The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
Study: NCT01910298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Reconstruction, Direct to Implant (DTI) with Strattice™

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Stage Breast Reconstruction
Study: NCT01407432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of folic acid
Description: Taking of placebo of folic acid by hanging oral route during 3 at 4 months
Study: NCT02342808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured center-based lifestyle intervention
Description: Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education and physician advice
Description: Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
Study: NCT04618536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen
Description: Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic sunscreen
Description: Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.